Telehealth Narcolepsy Prescribing: What PMHNPs Can Do in Michigan

If you’re a psychiatrist or psychiatric nurse practitioner looking to expand your telehealth practice, narcolepsy might not be the first condition that comes to mind. But here’s the reality: 160,000 Americans live with this debilitating sleep disorder, most struggle to find specialty care, and the majority of them can be managed effectively via telehealth—if you understand the prescribing landscape.

Let’s talk about what you can actually do, the regulatory maze you need to navigate, and why treating narcolepsy remotely might be more straightforward (and lucrative) than you think.

Why Narcolepsy Matters for Your Telehealth Practice

Narcolepsy is rare—affecting roughly 1 in 2,000 people—but underserved. Most patients wait years for a proper diagnosis, bouncing between primary care doctors who dismiss their excessive daytime sleepiness as ‘just being tired.’ Once diagnosed, they face another challenge: finding a provider who can prescribe and manage their medications long-term.

That’s where you come in.

Unlike general sleep disorders, narcolepsy requires ongoing medication management with controlled substances—typically Schedule II stimulants (Adderall, Ritalin, methylphenidate) or Schedule IV wakefulness agents (modafinil, armodafinil). These patients need:

• Monthly follow-ups (because Schedule II scripts have no refills)
• Dose titration and side effect monitoring
• Coordination with sleep specialists for diagnostic workups
• Someone who actually understands the difference between narcolepsy and ADHD prescribing

Most neurologists and sleep specialists focus on diagnosis but hand off medication management. Primary care physicians are often uncomfortable prescribing stimulants long-term. Psychiatrists and PMHNPs who understand psychopharmacology and controlled substance management are perfectly positioned to fill this gap via telehealth.

The economics work too: monthly medication management visits mean predictable, recurring revenue. Patients are typically stable and compliant (they need these meds to function), and with over 160 million Americans living in mental health provider shortage areas, telehealth access is literally a lifeline for narcolepsy patients in rural or underserved areas.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What Psychiatrists Can Do: Full Authority, Few Limits

If you’re a board-certified psychiatrist (MD or DO), here’s the good news: you have full prescriptive authority for narcolepsy medications in every state, provided you’re licensed where the patient is located and comply with controlled substance regulations.

Your Scope Includes:

Diagnosis & Initial Evaluation
While most narcolepsy patients will come to you with a sleep specialist’s diagnosis (polysomnography + multiple sleep latency test results), you can conduct initial psychiatric evaluations to rule out mimickers like depression, sleep apnea, or medication side effects. You’re qualified to review sleep studies and coordinate care with neurologists.

Full Medication Authority
You can prescribe:

• Schedule II stimulants: amphetamine/dextroamphetamine (Adderall), methylphenidate (Ritalin, Concerta), dextroamphetamine (Dexedrine)
• Schedule IV wakefulness agents: modafinil (Provigil), armodafinil (Nuvigil)
• Newer agents: solriamfetol (Sunosi), pitolisant (Wakix)
• Sodium oxybate (Xyrem/Xywav) for cataplexy—though this requires REMS program enrollment
• Adjunct medications: SSRIs or SNRIs for cataplexy, sedatives for nighttime fragmented sleep

As a physician, you’re not subject to the restrictive prescribing limits that plague nurse practitioners in many states. You can write 30-day supplies of Schedule II drugs (the federal limit for a single prescription) and use the ‘fill on specified date’ allowance to provide up to 90 days of treatment in one encounter—reducing administrative burden.

Telehealth Prescribing: Federal Allowances Through 2025
As of November 2024, the DEA extended pandemic-era telehealth flexibilities through December 2025. This means you can prescribe Schedule II–V controlled substances via telehealth without an initial in-person exam, as long as you conduct a proper video evaluation and follow state medical board telehealth standards.

After 2025, new DEA rules may require special telemedicine registration or a one-time in-person visit within 30 days of initiating controlled substances—but for now, you can fully manage narcolepsy patients remotely from first contact through ongoing care.

What You Need to Do:

1. Verify State Licensure
You must be licensed in the state where the patient physically resides during the telehealth visit. If you practice across multiple states, consider the Interstate Medical Licensure Compact (IMLC) for streamlined licensing.

2. Check the PDMP Every Time
Nearly every state requires prescribers to query the Prescription Drug Monitoring Program before writing a controlled substance prescription. In states like New York, this is mandatory for every Schedule II–IV prescription—no exceptions. Build this into your workflow (most EHRs integrate PDMP access).

3. Use EPCS (Electronic Prescribing of Controlled Substances)
Paper prescriptions for Schedule II drugs are obsolete and impossible in telehealth. You’ll need DEA-compliant e-prescribing software. Platforms like Klarity Health provide this infrastructure out of the box.

4. Document Like It’s In-Person
State medical boards require telehealth documentation to meet the same standard of care as in-person visits. That means:

• Verifying patient identity and location
• Obtaining informed consent for telehealth and controlled substances
• Documenting the clinical rationale for stimulant therapy
• Reviewing prior sleep study results or specialist recommendations
• Screening for misuse risk (personal/family history of substance use disorder)
• Recording vital signs or patient-reported metrics (blood pressure, weight, Epworth Sleepiness Scale scores)

State-Specific Physician Restrictions (Rare but Real)

Most states don’t impose physician-specific barriers for telehealth prescribing, but Florida is the exception. Florida law prohibits prescribing Schedule II controlled substances via telehealth unless it’s for a psychiatric disorder, inpatient care, hospice, or chronic pain management. Since narcolepsy is a neurological (not psychiatric) condition, a strict reading means you’d need at least one in-person exam to prescribe Adderall in Florida.

Workarounds:

• Use modafinil (Schedule IV)—allowed via telehealth in Florida
• If the patient has comorbid ADHD, you may qualify under the ‘psychiatric disorder’ exception
• Coordinate a local physician partner for the initial in-person visit, then manage ongoing care via telehealth

Outside of Florida, you’re generally free to practice narcolepsy telehealth psychiatry in any state where you hold a license, following that state’s standard telemedicine rules (audio-visual format required, proper consent, etc.).

What PMHNPs Can Do: State-by-State Reality Check

If you’re a psychiatric-mental health nurse practitioner, your authority to prescribe narcolepsy medications varies dramatically by state. Let’s break down the landscape so you know where you can practice independently and where you’ll need physician collaboration.

Full Practice States (Independent Authority)

California (Post-2026 Independence)
California’s AB 890 created a phased pathway to NP independence. As of 2023, experienced NPs can become ‘103 NPs’ (working in a group practice with physician oversight) and prescribe Schedule II–V drugs. Starting in January 2026, NPs with ≥3 years experience as a 103 NP can apply for ‘104 NP’ status—full independent practice within their specialty.

If you’re an experienced PMHNP in California, you’ll be able to diagnose and manage narcolepsy entirely on your own by 2026. Until then, you’ll need a physician with standardized procedures covering stimulant prescribing. California does require extra pharmacology coursework for Schedule II authority, but PMHNPs typically complete this during certification.

Illinois (Full Practice After 4,000 Hours)
Illinois grants Full Practice Authority (FPA) to NPs who complete 4,000 clinical hours under collaboration plus 250 hours of pharmacology continuing education. Once you achieve FPA, you can prescribe Schedule II–V controlled substances independently.

Important exceptions:

• Schedule II opioids require maintaining a physician consultation relationship (monthly discussions)
• Benzodiazepines prescribed continuously for >120 days require a physician consult
• Stimulants for narcolepsy have no such restriction—you can prescribe Adderall, modafinil, etc., completely independently once you have FPA

Illinois is one of the best states for PMHNPs treating narcolepsy via telehealth. The state also has strong telehealth parity laws and no additional controlled-substance restrictions for NPs beyond federal requirements.

New York (Independent After 3,600 Hours)
New York requires NPs to complete 3,600 hours (roughly 2 years) of practice under a written collaborative agreement. After hitting that threshold, you can practice and prescribe without any physician oversight or collaborative relationship.

New York NPs with ≥3,600 hours have the same prescriptive authority as physicians for narcolepsy medications. You’ll need to register with New York’s Bureau of Narcotic Enforcement, obtain your own DEA number, and check the I-STOP PDMP for every controlled substance prescription—but there are no NP-specific quantity limits or supervision requirements.

For newer NPs (under 3,600 hours), you’ll need a collaborative agreement that explicitly covers stimulant prescribing. Your collaborating physician must be available for consultation but doesn’t need to co-sign prescriptions.

Restricted Practice States (Physician Supervision Required)

Texas (Severely Limited)
Texas has the most restrictive NP regulations in the country for narcolepsy care. All NPs must practice under a Prescriptive Authority Agreement (PAA) with a supervising physician. Worse, Texas law prohibits NPs from prescribing Schedule II controlled substances in outpatient settings—period.

The only exceptions are:

• Hospital inpatient care (patient admitted ≥24 hours)
• Emergency department orders
• Hospice care for terminal patients

What this means: As a Texas PMHNP, you cannot prescribe Adderall or Ritalin for an outpatient narcolepsy patient via telehealth. Your supervising physician would need to write those prescriptions. You can prescribe Schedule III–V medications (modafinil, armodafinil) under your PAA, up to a 90-day supply.

Texas NPs interested in narcolepsy care will need a strong physician partnership where the MD handles Schedule II prescribing while you manage everything else—or stick to patients who respond to non-Schedule II wakefulness agents.

Pennsylvania (30-Day Limit on Schedule II)
Pennsylvania requires all NPs (CRNPs) to practice under a written collaborative agreement with a physician. You can prescribe Schedule II controlled substances, but Pennsylvania law limits you to 30-day supplies—you must notify your collaborating physician within 24 hours of prescribing.

Schedule III–IV medications (like modafinil) can be prescribed for up to 90 days. In practice, this means monthly visits for narcolepsy patients on stimulants—which aligns with best practices anyway, since Schedule II prescriptions can’t be refilled federally.

Your collaborative agreement must explicitly list the medications you’re authorized to prescribe, and your collaborating physician’s name must appear on prescriptions per Pennsylvania pharmacy rules.

Florida (7-Day Limit for Non-Psychiatric NPs)
Florida requires PMHNPs to practice under a physician collaborative agreement (autonomous practice is only for primary care NPs—and excludes psychiatric NPs). Florida law limits NP prescribing of Schedule II controlled substances to 7-day supplies for adults, with one important exception:

‘Psychiatric nurses’ (PMHNPs with additional certification and a psychiatrist collaboration) can prescribe Schedule II medications for psychiatric disorders beyond 7 days.

Here’s the gray area: Narcolepsy isn’t a psychiatric disorder, so a strict reading suggests the 7-day limit applies. However, if your patient has comorbid ADHD or you’re treating the medication as a ‘psychiatric medication,’ you might qualify for the exception.

Practical reality: Most Florida PMHNPs managing narcolepsy either:

• Work with their collaborating psychiatrist to write ongoing stimulant prescriptions
• Use modafinil (Schedule IV)—no 7-day limit applies
• Arrange a local physician to handle Schedule II prescriptions while managing everything else via telehealth

Florida also prohibits telehealth prescribing of Schedule II drugs except for psychiatric treatment, inpatient care, or chronic pain—adding another layer of complexity.

State-by-State Comparison Table

Medication Management Workflow: Monthly Visits That Actually Pay

Narcolepsy medication management is one of the most structured, predictable workflows in psychiatric prescribing—which makes it efficient and financially viable via telehealth.

Typical Visit Structure (15-20 Minutes)

Initial Evaluation (30-45 minutes)

• Verify diagnosis (review sleep study results, neurology notes)
• Comprehensive psychiatric and medical history
• Assess current symptoms (Epworth Sleepiness Scale, frequency of sleep attacks, cataplexy episodes)
• Screen for contraindications (cardiovascular disease, substance use history, pregnancy)
• Discuss treatment options, side effects, and monitoring plan
• Obtain informed consent for controlled substances
• Initiate first medication (typically start with modafinil or low-dose stimulant)
• PDMP check and e-prescribe 30-day supply
• Billing: 99204 or 99205 (~$150-$200 reimbursement)

Monthly Follow-Ups (15-20 minutes)

• Symptom review: Are they staying awake during the day? Any sleep attacks? Cataplexy control?
• Side effect assessment: Blood pressure, heart rate, weight, appetite, sleep at night, anxiety
• Medication adherence: Any missed doses? Pharmacy issues?
• Dose adjustment if needed (titrate up for inadequate response, reduce if side effects)
• Lifestyle/sleep hygiene counseling (brief)
• PDMP check
• E-prescribe next 30-day supply
• Billing: 99213 or 99214 (~$80-$130)

Quarterly or Biannual Check-Ins (20-30 minutes)

• Comprehensive review of medication effectiveness
• Coordination with sleep specialist or PCP if needed
• Updated lab work if on certain medications (liver function for sodium oxybate, etc.)
• Prior authorization renewal for expensive meds
• Billing: 99214 or 99215

Reimbursement Reality

Insurance Billing
Most commercial insurers and Medicare now cover telehealth psychiatry visits at parity with in-person care (in states with parity laws—which includes CA, NY, IL, PA, TX, and most others post-COVID).

• Medicare: Reimburses telehealth mental health visits at full physician fee schedule rates through at least 2024 (likely extended). For NPs, Medicare pays 85% of the physician rate.
• Private Insurance: Varies by plan, but mental health providers historically receive ~22% lower reimbursement than other specialists—a mental health parity violation many states are addressing through new legislation. Narcolepsy management may code as neurological rather than psychiatric, potentially avoiding some of this gap.
• Medicaid: Most state Medicaid programs now cover telehealth at parity.

Per-Patient Annual Revenue (Insurance)

• Initial visit: ~$150-$200
• 11 monthly follow-ups: ~$80-$130 × 11 = $880-$1,430
• Total per patient/year: $1,000-$1,600

Not massive for a single patient, but narcolepsy patients are:

• Highly retentive: They need meds indefinitely; churn is low
• Efficient: 15-minute visits mean you can see 3-4 patients/hour
• Stackable: A panel of 50 active narcolepsy patients generates $50,000-$80,000/year with minimal overhead

Cash-Pay Alternative
Many psychiatrists treating narcolepsy have moved to cash-pay or subscription models to avoid insurance hassles (especially prior authorizations for expensive meds). Typical pricing:

• Initial evaluation: $300-$400
• Monthly follow-ups: $100-$150
• Annual per-patient revenue: $1,500-$2,000+

Patients desperate for specialized care—especially in underserved states like Texas—will pay out-of-pocket if it means accessing a provider who actually understands narcolepsy.

Administrative Burden (The Hidden Cost)

One reality of narcolepsy care: prior authorizations are a pain. Modafinil, pitolisant, solriamfetol, and especially sodium oxybate often require extensive documentation:

• Sleep study results
• Neurologist referral or diagnosis confirmation
• Proof of failed first-line treatments (step therapy)
• Peer-to-peer calls with insurance medical directors

This is unpaid work that can consume 30-60 minutes per patient initially. Platforms that provide prior authorization support staff or have streamlined processes with major insurers can dramatically improve your quality of life.

The Adderall shortage (ongoing since mid-2022) has also added extra burden—patients call in panicked when their pharmacy can’t fill prescriptions, requiring you to quickly switch medications or hunt for alternative pharmacies. This is less of an issue with modafinil or newer agents, but it’s something to anticipate if prescribing amphetamines.

Compliance Checklist: Avoid Regulatory Pitfalls

Whether you’re an MD or NP, treating narcolepsy via telehealth with controlled substances means meticulous compliance. Here’s your checklist:

Federal Requirements (All States)

• [ ] Valid DEA registration (must include state where patient is located)
• [ ] EPCS-enabled e-prescribing system (DEA two-factor authentication)
• [ ] Proper practitioner-patient relationship via audio-video (federal standard during telehealth waivers)
• [ ] Schedule II prescriptions limited to 30-day supply (can provide up to 90 days using multiple scripts with ‘do not fill until’ dates)
• [ ] No refills on Schedule II (new prescription required each month)
• [ ] Maintain records for 2-3 years (varies by state)

State-Specific Requirements

PDMP Checks

• New York: Query I-STOP for every Schedule II-IV prescription
• California: Query CURES before initial controlled Rx and at least every 4 months for ongoing prescriptions
• Texas: Check PDMP at initial prescription and at least annually (or if signs of misuse)
• Illinois: Check before prescribing opioids/benzos (stimulants not explicitly mandated but best practice)
• Pennsylvania: Check PDMP before initial controlled Rx and periodically for ongoing therapy
• Florida: Check E-FORCSE before prescribing controlled substances and quarterly for ongoing patients

Collaborative Agreements (NPs)

• Texas: PAA must be filed with Texas Medical Board; physician can supervise max 7 APRNs
• Pennsylvania: Written agreement required on file at practice location; physician must review sample of charts
• Florida: Protocol filed with Board of Nursing; supervising physician must review percentage of patient records
• New York (under 3,600 hrs): Written collaborative agreement covering scope and medications; not filed with state but kept on-site
• Illinois (under FPA): Written collaborative agreement; must submit to state if under traditional collaboration

Telehealth-Specific Rules

• Florida: No Schedule II via telehealth for non-psychiatric conditions (use modafinil or ensure in-person visit)
• All states: Audio-visual format required (phone-only insufficient for controlled substances)
• Texas: Telemedicine standard of care must be equivalent to in-person
• California, New York, Illinois, Pennsylvania: Telehealth parity laws ensure reimbursement equity

Risk Management Best Practices

1. Document everything: Clinical rationale for stimulant choice, dose adjustments, PDMP checks, patient education on misuse risks
2. Use informed consent forms: Specifically for controlled substances, outlining risks, monitoring plan, and consequences of misuse
3. Screen for red flags: Early refill requests, lost prescriptions, multiple providers, inconsistent symptom reports
4. Have a diversion protocol: What do you do if you suspect misuse? Document your policy and follow it consistently
5. Coordinate with sleep specialists: Request updated sleep studies every 2-3 years; maintain communication with diagnosing neurologist
6. Monitor vitals remotely: Use patient-reported BP/HR or coordinate with local PCP for labs and EKGs if high-dose stimulants

Why Join a Platform Like Klarity Health for Narcolepsy Care

Let’s be honest: the regulatory complexity, prior authorization burden, and state-by-state variations make narcolepsy prescribing via telehealth a logistical headache—unless you have the right infrastructure.

Most solo practitioners or small telehealth groups struggle with:

• Multi-state licensing costs: $500-$2,000 per state, annual renewals, separate DEA registrations
• EPCS software and PDMP integrations: Most basic telehealth platforms don’t include DEA-compliant controlled substance e-prescribing
• Prior authorization support: You can’t bill for the 2 hours you spend fighting with insurance for Xyrem approval
• Patient acquisition: How do you find narcolepsy patients who need your specialty care?
• Compliance updates: Keeping track of DEA rule changes, state scope-of-practice amendments, and PDMP requirements across multiple states

This is where a specialized telehealth platform changes the economics entirely.

What Klarity Health Provides:

Built-In Compliance Infrastructure

• EPCS-enabled e-prescribing integrated into the EHR
• Automatic PDMP integrations for all 50 states
• State-specific prescribing alerts (e.g., Florida Schedule II restrictions, Texas NP limitations)
• Telehealth consent templates and documentation workflows meeting state standards

Pre-Qualified Patient Flow
Instead of spending thousands on Google Ads or Psychology Today listings hoping someone with narcolepsy finds you, Klarity uses a pay-per-appointment model: you only pay when a qualified patient books with you.

• Patients are already matched to your specialty and availability
• No upfront marketing spend or monthly subscriptions
• Both insurance and cash-pay patient options
• You control your schedule—work as much or as little as you want

Prior Authorization Support
Dedicated staff handle the paperwork for medication approvals, peer-to-peer scheduling, and insurance appeals—saving you hours per patient.

Multi-State Licensing Support
Guidance on which states make sense for your practice (e.g., avoiding Texas if you’re an NP wanting to prescribe stimulants), assistance with licensure applications, and tracking of renewal dates.

Collaborative Agreements (for NPs)
In states requiring physician collaboration (TX, PA, FL), Klarity can facilitate connections with supervising psychiatrists or handle the administrative setup of collaborative agreements.

The ROI Argument

DIY Telehealth Marketing Reality:

• Google Ads for ‘narcolepsy treatment’ or ‘psychiatrist near me’: $15-40/click
• Conversion rate to booked appointment: 2-5%
• Cost per booked patient: $200-500+ (and that’s if you know what you’re doing)
• SEO takes 6-12 months of consistent investment before meaningful traffic
• Psychology Today/Zocdoc monthly fees: $30-100/month + per-booking fees ($35-100)
• Total monthly marketing spend to sustain a practice: $3,000-5,000+ with uncertain ROI

Klarity Health Model:

• No upfront marketing spend
• Standard listing fee per new patient lead (only pay when they book)
• Pre-qualified patients already diagnosed or seeking narcolepsy care
• Guaranteed ROI: You know exactly what each patient costs, and since narcolepsy patients require monthly follow-ups, lifetime value is high

If a DIY practice spends $5,000/month on marketing to acquire 10-15 new patients (with months of ramp-up), versus joining Klarity and seeing the same patient volume from day one with no wasted ad spend—the economics are clear.

FAQ: Narcolepsy Telehealth Prescribing

Can psychiatrists prescribe stimulants for narcolepsy via telehealth?
Yes. Psychiatrists (MD/DO) have full authority to prescribe Schedule II stimulants (Adderall, Ritalin) and other narcolepsy medications via telehealth in all 50 states, provided they are licensed in the patient’s state. Federal DEA allowances for telehealth prescribing of controlled substances are extended through December 2025. A few states (like Florida) have additional restrictions on Schedule II telehealth prescribing for non-psychiatric conditions—check your state’s specific rules.

Can nurse practitioners prescribe narcolepsy medications independently?
It depends on your state. PMHNPs in full-practice states like Illinois (after 4,000 hours), New York (after 3,600 hours), and California (after 2026 for experienced NPs) can prescribe narcolepsy medications independently, including Schedule II stimulants. In restricted-practice states like Texas, Pennsylvania, and Florida, you’ll need a physician collaborative agreement. Texas prohibits NPs from prescribing Schedule II drugs in outpatient settings entirely, so you’d be limited to modafinil or need your collaborating physician to write stimulant prescriptions.

Do I need to see narcolepsy patients in person before prescribing controlled substances?
Currently, no. The DEA’s pandemic-era telehealth flexibilities allow prescribing Schedule II-V controlled substances after a telehealth evaluation without an initial in-person visit, extended through at least December 2025. After that, new DEA telemedicine registration rules may require an in-person exam within a certain timeframe—stay updated on federal regulations. Some states have stricter rules (e.g., Florida prohibits telehealth Schedule II prescribing for narcolepsy), so always check state law.

How often do narcolepsy patients need medication management visits?
Typically monthly during initial dose titration (first 3-6 months), then every 1-3 months for stable patients. Since Schedule II stimulants can’t be refilled, monthly visits align with the need for new prescriptions. These visits are brief (15-20 minutes), focusing on symptom control, side effects, and prescription renewals—making them efficient and financially sustainable via telehealth.

What’s the difference between prescribing for narcolepsy vs. ADHD?
Clinically, narcolepsy patients often require higher stimulant doses and sometimes take doses later in the day (to combat afternoon sleepiness), whereas ADHD dosing is typically morning-only. Narcolepsy patients may also need combination therapy (stimulant + sodium oxybate for cataplexy, or adding an SSRI). Legally, there’s no difference in DEA scheduling—both conditions use the same Schedule II stimulants—but narcolepsy diagnosis requires objective testing (sleep studies) whereas ADHD is clinical. Insurance prior authorizations for narcolepsy meds are often more stringent, requiring proof of sleep study results.

Do I need special training to treat narcolepsy?
No formal certification is required, but you should be comfortable with:

• Reviewing polysomnography and MSLT results (or coordinating with a sleep specialist who provides diagnosis)
• Managing Schedule II stimulant therapy and monitoring cardiovascular side effects
• Understanding narcolepsy subtypes (type 1 with cataplexy vs. type 2)
• Using wakefulness agents like modafinil and newer medications (Sunosi, Wakix)
• Handling sodium oxybate REMS program enrollment if treating cataplexy

Most psychiatrists already have this expertise from managing ADHD and psychopharmacology. A brief literature review or CME course on sleep disorders is sufficient.

How do I handle the Adderall shortage?
The amphetamine shortage (ongoing since 2022) has forced flexibility. If a patient’s pharmacy can’t fill their Adderall prescription:

• Switch to methylphenidate (Ritalin, Concerta)—a different Schedule II stimulant less affected by shortages
• Try modafinil or armodafinil (Schedule IV, widely available)
• Consider newer agents like solriamfetol (Sunosi) if insurance covers it
• Help patients find alternative pharmacies (call ahead before sending e-prescriptions)

Telehealth makes this easier—you can quickly adjust and re-prescribe electronically without requiring another in-person visit.

What if my state requires a collaborative agreement and I don’t have a physician partner?
Platforms like Klarity Health can facilitate physician partnerships in states requiring NP collaboration (Texas, Pennsylvania, Florida). Alternatively, reach out to local psychiatrists or sleep specialists willing to serve as collaborating physicians. Many telehealth-friendly MDs are open to collaborative agreements with experienced NPs for a reasonable consulting fee or percentage of revenue.

Are narcolepsy medications covered by insurance?
Most are, but prior authorizations are common. Generic modafinil and amphetamine salts are usually straightforward. Newer agents (Sunosi, Wakix) and especially sodium oxybate (Xyrem/Xywav) require extensive documentation—sleep study results, proof of diagnosis, sometimes documentation of failed first-line treatments. This is where having prior authorization support from your platform is invaluable. If insurance denies coverage, discuss cash-pay options with patients (generic modafinil runs ~$30-50/month out-of-pocket; Adderall is similar).

Can I bill for narcolepsy medication management if I’m a psychiatrist but the patient’s diagnosis is neurological?
Yes. You bill evaluation and management (E/M) codes (99213, 99214, etc.) based on the complexity of the visit, not the specialty of the diagnosis. Use ICD-10 code G47.4__ for narcolepsy (specific subtype). Some insurers may process this under the patient’s medical benefit rather than behavioral health, which can actually result in better reimbursement since mental health parity violations are common. As long as you’re providing legitimate medical management within your scope, billing is appropriate.

Ready to Fill a Critical Gap in Sleep Medicine?

Narcolepsy patients need you. They’re stuck between overbooked sleep specialists who can diagnose but not manage long-term, and primary care physicians uncomfortable prescribing stimulants. You—whether a psychiatrist with full prescriptive authority or an experienced PMHNP in a favorable state—have the expertise to provide life-changing care.

The regulatory landscape is complex, but manageable. Federal telehealth allowances make remote prescribing possible through at least 2025. State scope-of-practice laws are slowly expanding NP authority. And platforms that handle the infrastructure—licensing, EPCS, prior authorizations, patient acquisition—make the economics work without the typical $5,000+/month marketing gamble.

Klarity Health’s telehealth platform connects psychiatrists and PMHNPs with patients who need exactly what you offer: expert medication management for complex conditions like narcolepsy. No upfront marketing spend, no wasted ad budgets, just qualified patients and the clinical infrastructure to deliver compliant, high-quality care.

If you’re ready to expand into an underserved niche where your pharmacology expertise truly matters—and where patients will stick with you for years of monthly follow-ups—explore joining Klarity Health’s provider network today.

Sources & Citations

1. Axios (Nov 18, 2024) – ‘DEA and HHS extend COVID-era telehealth prescribing flexibility for controlled substances through December 2025.’ Axios Health Policy. Retrieved from https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

2. Texas Medical Board – ‘Who Can Prescribe Schedule II Drugs Under Physician Delegation?’ FAQ confirming NP/PA may only prescribe Schedule II in hospital inpatient or hospice settings. Retrieved from https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation

3. California Board of Registered Nursing – ‘AB 890: Nurse Practitioner Practice’ outlining the 103 NP and 104 NP categories and timeline for independent practice

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,person%20doctor%27s%20visit%20for%20the
• https://natlawreview.com/article/new-florida-law-allows-telemedicine-prescribing-controlled-substances#:~:text=controlled%20substances%20via%20telemedicine%2C%20with,more%20on
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,drugs%2C%20such%20as
• https://www.ilga.gov/legislation/ILCS/details?ActID=1312&ActName=Nurse+Practice+Act.&ChapAct=225+ILCS+65%2F&Chapter=&ChapterID=24&MajorTopic=&Print=True&SeqEnd=17850000&SeqStart=16500000#:~:text=,require%20a%20physician%20name%3B
• https://www.rivkinrounds.com/2022/04/new-law-allows-experienced-nps-to-practice-independently-in-ny/#:~:text=New%20York%E2%80%99s%202023%20state%20budget%2C,practice%20without%20a%20collaborative%20relationship
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=%2A%20103%20NP%20,focus%20of%20their%20National%20Certification
• https://www.rn.ca.gov/practice/ab890.shtml#:~:text=Please%20note%2C%20the%20law%20requires,certify%20104%20NPs%20until%202026
• https://www.tmb.state.tx.us/274-who-can-prescribe-schedule-ii-drugs-under-physician-delegation#:~:text=1.%20in%20a%20hospital%20facility,has%20elected%20to%20receive%20hospice
• https://www.flsenate.gov/Laws/Statutes/2021/Chapter464/All#:~:text=match%20at%20L1566%20limit%20the,455
• https://www.pacodeandbulletin.gov/Display/pacode?file=%2Fsecure%2Fpacode%2Fdata%2F049%2Fchapter21%2Fs21.284.html#:~:text=,may%20not%20delegate%20prescriptive%20authority